Skip to main content
SpringerLink
Log in
Book cover

Ovarian Cancer pp 297–318Cite as

Cell Adhesion in Ovarian Cancer

  • Chapter
  • First Online:

Part of the book series: Cancer Treatment and Research ((CTAR,volume 149))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  2. Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol. 2000;299(3):551–572.

    Article  CAS  PubMed  Google Scholar 

  3. Yagi T, Takeichi M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev. 2000;14(10):1169–1180.

    CAS  PubMed  Google Scholar 

  4. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251(5000):1451–1455.

    Article  CAS  PubMed  Google Scholar 

  5. Goodwin M, Yap AS. Classical cadherin adhesion molecules: coordinating cell adhesion, signaling and the cytoskeleton. J Mol Histol. 2004;35(8–9):839–844.

    Article  CAS  PubMed  Google Scholar 

  6. McCrea PD, Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science. 1991;254(5036):1359–13561.

    Article  CAS  PubMed  Google Scholar 

  7. Aberle H, Butz S, Stappert J, Weissig H, Kemler R, Hoschuetzky H. Assembly of the cadherin–catenin complex in vitro with recombinant proteins. J Cell Sci. 1994;107(Pt 12):3655–3663.

    CAS  PubMed  Google Scholar 

  8. Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI. Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell. 2005;123(5):903–915.

    Article  CAS  PubMed  Google Scholar 

  9. Kobielak A, Fuchs E. Alpha-catenin: at the junction of intercellular adhesion and actin dynamics. Nat Rev Mol Cell Biol. 2004;5(8):614–625.

    Article  CAS  PubMed  Google Scholar 

  10. Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci USA. 1995;92(19):8813–8817.

    Article  CAS  PubMed  Google Scholar 

  11. Daniel JM, Reynolds AB. The tyrosine kinase substrate p120cas binds directly to E-cadherin but not to the adenomatous polyposis coli protein or alpha-catenin. Mol Cell Biol. 1995;15(9):4819–4824.

    CAS  PubMed  Google Scholar 

  12. Xiao K, Allison DF, Buckley KM, et al. Cellular levels of p120 catenin function as a set point for cadherin expression levels in microvascular endothelial cells. J Cell Biol. 2003;163(3):535–545.

    Article  CAS  PubMed  Google Scholar 

  13. Huber AH, Stewart DB, Laurents DV, Nelson WJ, Weis WI. The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J Biol Chem. 2001;276(15):12301–12309.

    Article  CAS  PubMed  Google Scholar 

  14. Chen YT, Stewart DB, Nelson WJ. Coupling assembly of the E-cadherin/beta-catenin complex to efficient endoplasmic reticulum exit and basal-lateral membrane targeting of E-cadherin in polarized MDCK cells. J Cell Biol. 1999;144(4):687–699.

    Article  CAS  PubMed  Google Scholar 

  15. Daugherty RL, Gottardi CJ. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology (Bethesda) 2007;22:303–309.

    CAS  Google Scholar 

  16. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol. 2001;153(5):1049–1060.

    Article  CAS  PubMed  Google Scholar 

  17. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303(5663):1483–1487.

    Article  CAS  PubMed  Google Scholar 

  18. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996;382(6592):638–642.

    Article  CAS  PubMed  Google Scholar 

  19. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev. 1997;11(24):3286–3305.

    Article  CAS  PubMed  Google Scholar 

  20. Huber O, Bierkamp C, Kemler R. Cadherins and catenins in development. Curr Opin Cell Biol. 1996;8(5):685–691.

    Article  CAS  PubMed  Google Scholar 

  21. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer. 2002;34(3):255–268.

    Article  CAS  PubMed  Google Scholar 

  22. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837–1851.

    CAS  PubMed  Google Scholar 

  23. Bullions LC, Notterman DA, Chung LS, Levine AJ. Expression of wild-type alpha-catenin protein in cells with a mutant alpha-catenin gene restores both growth regulation and tumor suppressor activities. Mol Cell Biol. 1997;17(8):4501–4508.

    CAS  PubMed  Google Scholar 

  24. Andl CD, Rustgi AK. No one-way street: cross-talk between e-cadherin and receptor tyrosine kinase (RTK) signaling: a mechanism to regulate RTK activity. Cancer Biol Ther. 2005;4(1):28–31.

    Article  CAS  PubMed  Google Scholar 

  25. Hoschuetzky H, Aberle H, Kemler R. Beta-catenin mediates the interaction of the cadherin–catenin complex with epidermal growth factor receptor. J Cell Biol. 1994;127(5):1375–1380.

    Article  CAS  PubMed  Google Scholar 

  26. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004;23(8):1739–1748.

    Article  CAS  PubMed  Google Scholar 

  27. Fujita Y, Krause G, Scheffner M, et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol. 2002;4(3):222–231.

    Article  CAS  PubMed  Google Scholar 

  28. Kaibuchi K, Kuroda S, Fukata M, Nakagawa M. Regulation of cadherin-mediated cell–cell adhesion by the Rho family GTPases. Curr Opin Cell Biol. 1999;11(5):591–596.

    Article  CAS  PubMed  Google Scholar 

  29. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–142.

    Article  CAS  PubMed  Google Scholar 

  30. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004;4(2):118–132.

    CAS  PubMed  Google Scholar 

  31. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548–558.

    Article  CAS  PubMed  Google Scholar 

  32. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66(1):107–119.

    Article  CAS  PubMed  Google Scholar 

  33. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153(2):333–339.

    CAS  PubMed  Google Scholar 

  34. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin–catenin adhesion system in signaling and cancer. J Clin Invest. 2002;109(8):987–991.

    CAS  PubMed  Google Scholar 

  35. Cano A, Perez-Moreno MA, Rodrigo I, et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2(2):76–83.

    Article  CAS  PubMed  Google Scholar 

  36. Perez-Moreno MA, Locascio A, Rodrigo I, et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem. 2001;276(29):27424–27431.

    Article  CAS  PubMed  Google Scholar 

  37. Davies BR, Worsley SD, Ponder BA. Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology. 1998;32(1):69–80.

    Article  CAS  PubMed  Google Scholar 

  38. Sundfeldt K, Piontkewitz Y, Ivarsson K, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer. 1997;74(3):275–280.

    Article  CAS  PubMed  Google Scholar 

  39. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol. 1998;25(3):281–304.

    CAS  PubMed  Google Scholar 

  40. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest. 1994;71(4):510–518.

    CAS  PubMed  Google Scholar 

  41. Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer. 1996;69(6):429–436.

    Article  CAS  PubMed  Google Scholar 

  42. Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell–cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer. 1994;58(3):393–399.

    Article  CAS  PubMed  Google Scholar 

  43. Ross JS, del Rosario AD, Figge HL, Sheehan C, Fisher HA, Bui HX. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol. 1995;26(9):940–944.

    Article  CAS  PubMed  Google Scholar 

  44. Sundfeldt K. Cell–cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol Cell Endocrinol. 2003;202(1–2):89–96.

    CAS  PubMed  Google Scholar 

  45. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992;52(18):5104–5109.

    CAS  PubMed  Google Scholar 

  46. Vanderburg CR, Hay ED. E-cadherin transforms embryonic corneal fibroblasts to stratified epithelium with desmosomes. Acta Anat (Basel). 1996;157(2):87–104.

    Article  CAS  Google Scholar 

  47. Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD. Cadherin switching in ovarian cancer progression. Int J Cancer. 2003;106(2):172–177.

    Article  CAS  PubMed  Google Scholar 

  48. Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC. P-cadherin expresion in breast cancer: a review. Breast Cancer Res. 2007;9:214–225.

    Article  PubMed  Google Scholar 

  49. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest. 1993;91(2):379–387.

    Article  CAS  PubMed  Google Scholar 

  50. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J. 1995;9(10):866–873.

    CAS  PubMed  Google Scholar 

  51. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets. 2007;11(11):1473–1491.

    Article  CAS  PubMed  Google Scholar 

  52. Alessandro R, Seidita G, Flugy AM, et al. Role of S128R polymorphism of E-selectin in colon metastasis formation. Int J Cancer. 2007;121(3):528–535.

    Article  CAS  PubMed  Google Scholar 

  53. Ferroni P, Roselli M, Martini F, et al. Prognostic value of soluble P-selectin levels in colorectal cancer. Int J Cancer. 2004;111(3):404–408.

    Article  CAS  PubMed  Google Scholar 

  54. Flugy AM, D'Amato M, Russo D, et al. E-selectin modulates the malignant properties of T84 colon carcinoma cells. Biochem Biophys Res Commun. 2002;293(3):1099–1106.

    Article  CAS  PubMed  Google Scholar 

  55. Roselli M, Mineo TC, Martini F, et al. Soluble selectin levels in patients with lung cancer. Int J Biol Markers. 2002;17(1):56–62.

    CAS  PubMed  Google Scholar 

  56. Kannagi R. Regulatory roles of carbohydrate ligands for selectins in the homing of lymphocytes. Curr Opin Struct Biol. 2002;12(5):599–608.

    Article  CAS  PubMed  Google Scholar 

  57. Munro JM, Lo SK, Corless C, et al. Expression of sialyl-Lewis X, an E-selectin ligand, in inflammation, immune processes, and lymphoid tissues. Am J Pathol. 1992;141(6):1397–1408.

    CAS  PubMed  Google Scholar 

  58. Brandley BK, Swiedler SJ, Robbins PW. Carbohydrate ligands of the LEC cell adhesion molecules. Cell. 1990;63(5):861–863.

    Article  CAS  PubMed  Google Scholar 

  59. Phillips ML, Nudelman E, Gaeta FC, et al. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science. 1990;250(4984):1130–1132.

    Article  CAS  PubMed  Google Scholar 

  60. Springer TA. Adhesion receptors of the immune system. Nature. 1990;346(6283):425–434.

    Article  CAS  PubMed  Google Scholar 

  61. Mayadas TN. Selectins. In: Brodt P, ed. Cell Adhesion and Invasion in Cancer Metastasis. Austin, Texas: R.G Landes Company; 1996:77–92.

    Google Scholar 

  62. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA. 1987;84(24):9238–9242.

    Article  CAS  PubMed  Google Scholar 

  63. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, Hauptmann S. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol. 2002;161(4):1215–1221.

    CAS  PubMed  Google Scholar 

  64. Witz IP. The involvement of selectins and their ligands in tumor-progression. Immunol Lett. 2006;104(1–2):89–93.

    Article  CAS  PubMed  Google Scholar 

  65. Banks RE, Gearing AJ, Hemingway IK, Norfolk DR, Perren TJ, Selby PJ. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Br J Cancer. 1993;68(1):122–124.

    CAS  PubMed  Google Scholar 

  66. Ferdeghini M, Gadducci A, Prontera C, et al. Preoperative serum intercellular adhesion molecule-1 (ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) in patients with epithelial ovarian cancer. Anticancer Res. 1995;15(5B):2255–2260.

    CAS  PubMed  Google Scholar 

  67. Kanoh A, Seko A, Ideo H, et al. Ectopic expression of N-acetylglucosamine 6-O-sulfotransferase 2 in chemotherapy-resistant ovarian adenocarcinomas. Glycoconj J. 2006;23(5–6):453–460.

    Article  CAS  PubMed  Google Scholar 

  68. Uchimura K, El-Fasakhany FM, Hori M, et al. Specificities of N-acetylglucosamine-6-O-sulfotransferases in relation to L-selectin ligand synthesis and tumor-associated enzyme expression. J Biol Chem. 2002;277(6):3979–3984.

    Article  CAS  PubMed  Google Scholar 

  69. Tamada Y, Iida S, Aoki D, Nozawa S, Irimura T. Carbohydrate epitopes and mucins expressed by 17 human ovarian carcinoma cell lines. Oncol Res. 1999;11(5):233–241.

    CAS  PubMed  Google Scholar 

  70. Federici MF, Kudryashov V, Saigo PE, Finstad CL, Lloyd KO. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int J Cancer. 1999;81(2):193–198.

    Article  CAS  PubMed  Google Scholar 

  71. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267–277.

    Article  CAS  PubMed  Google Scholar 

  72. Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract. 2005;201(7):479–486.

    Article  CAS  PubMed  Google Scholar 

  73. Nakahara S, Raz A. Biological modulation by lectins and their ligands in tumor progression and metastasis. Curr Med Chem Anticancer Agents. 2008;8(1):22–36.

    Article  CAS  Google Scholar 

  74. Aychek TMK, Sagi-Assif O, Levy-Nissenbaum O, Israeli-Amit M, Pasmanik-Chor M, Jacob-Hirsch J, Amariglio N, Rechavi G, Witz IP. E-selectin regulates gene expression in metastatic colorectal carcinoma cells and enhances HMGB1 release. Int J Cancer. 2008 Oct 15;123(8):1741–50.

    Google Scholar 

  75. Mannori G, Santoro D, Carter L, Corless C, Nelson RM, Bevilacqua MP. Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol. 1997;151(1):233–243.

    CAS  PubMed  Google Scholar 

  76. Khatib AM, Fallavollita L, Wancewicz EV, Monia BP, Brodt P. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. Cancer Res. 2002;62(19):5393–5398.

    CAS  PubMed  Google Scholar 

  77. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. 2001;98(6):3352–3357.

    Article  CAS  PubMed  Google Scholar 

  78. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A. 2002;99(4):2193–2198.

    Article  CAS  PubMed  Google Scholar 

  79. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81(4):1012–1019.

    Article  CAS  PubMed  Google Scholar 

  80. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998;95(16):9325–9330.

    Article  CAS  PubMed  Google Scholar 

  81. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59(6):1295–1300.

    CAS  PubMed  Google Scholar 

  82. Burdick MM, McCarty OJ, Jadhav S, Konstantopoulos K. Cell–cell interactions in inflammation and cancer metastasis. IEEE Eng Med Biol Mag. 2001;20(3):86–91.

    Article  CAS  PubMed  Google Scholar 

  83. Gurney D, Poole C, Kehoe S, Lip GY, Blann AD. Soluble P-selectin is influenced by cancer chemotherapy. Platelets. 2001;12(1):37–38.

    Article  CAS  PubMed  Google Scholar 

  84. Nguyen M, Eilber FR, Defrees S. Novel synthetic analogs of sialyl Lewis X can inhibit angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 1996;228(3):716–723.

    Article  CAS  PubMed  Google Scholar 

  85. Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev. 2008;27(1):19–30.

    Article  CAS  PubMed  Google Scholar 

  86. Nguyen M, Folkman J, Bischoff J. 1-Deoxymannojirimycin inhibits capillary tube formation in vitro. Analysis of N-linked oligosaccharides in bovine capillary endothelial cells. J Biol Chem. 1992;267(36):26157–26165.

    CAS  PubMed  Google Scholar 

  87. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 2004;95(5):377–384.

    Article  CAS  PubMed  Google Scholar 

  88. Kneuer C, Ehrhardt C, Radomski MW, Bakowsky U. Selectins – potential pharmacological targets? Drug Discov Today. 2006;11(21–22):1034–1040.

    Article  CAS  PubMed  Google Scholar 

  89. Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003;9(6):263–268.

    Article  CAS  PubMed  Google Scholar 

  90. Bhushan M, Bleiker TO, Ballsdon AE, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol. 2002;146(5):824–831.

    Article  CAS  PubMed  Google Scholar 

  91. Tsuchihashi S, Fondevila C, Shaw GD, et al. Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: protection from ischemia-reperfusion injury in liver transplantation. J Immunol. 2006;176(1):616–624.

    CAS  PubMed  Google Scholar 

  92. Kaila N, Thomas BET. Design and synthesis of sialyl Lewis(x) mimics as E- and P-selectin inhibitors. Med Res Rev. 2002;22(6):566–601.

    Article  CAS  PubMed  Google Scholar 

  93. Romano SJ. Selectin antagonists: therapeutic potential in asthma and COPD. Treat Respir Med. 2005;4(2):85–94.

    Article  CAS  PubMed  Google Scholar 

  94. Bedard PW, Clerin V, Sushkova N, et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther. 2008;324(2):497–506.

    Article  CAS  PubMed  Google Scholar 

  95. Kaila N, Janz K, Huang A, et al. 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists. J Med Chem. 2007;50(1):40–64.

    Article  CAS  PubMed  Google Scholar 

  96. Davidson B, Espina V, Steinberg SM, et al. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clin Cancer Res. 2006;12(3 Pt 1):791–799.

    Article  CAS  PubMed  Google Scholar 

  97. Hodgson L, Kohn EC, Dong C. Extracellular lipid-mediated signaling in tumor-cell activation and pseudopod protrusion. Int J Cancer. 2000;88(4):593–600.

    Article  CAS  PubMed  Google Scholar 

  98. Kassis J, Klominek J, Kohn EC. Tumor microenvironment: what can effusions teach us? Diagn Cytopathol. 2005;33(5):316–319.

    Article  PubMed  Google Scholar 

  99. Galbraith CG, Yamada KM, Galbraith JA. Polymerizing actin fibers position integrins primed to probe for adhesion sites. Science. 2007;315(5814):992–995.

    Article  CAS  PubMed  Google Scholar 

  100. Basson MD, Yu CF, Herden-Kirchoff O, et al. Effects of increased ambient pressure on colon cancer cell adhesion. J Cell Biochem. 2000;78(1):47–61.

    Article  CAS  PubMed  Google Scholar 

  101. Thamilselvan V, Basson MD. Pressure activates colon cancer cell adhesion by inside-out focal adhesion complex and actin cytoskeletal signaling. Gastroenterology. 2004;126(1):8–18.

    Article  CAS  PubMed  Google Scholar 

  102. Basson MD. An intracellular signal pathway that regulates cancer cell adhesion in response to extracellular forces. Cancer Res. 2008;68(1):2–4.

    Article  CAS  PubMed  Google Scholar 

  103. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91–100.

    Article  PubMed  Google Scholar 

  104. Ahmed N, Riley C, Oliva K, Rice G, Quinn M. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer. 2005;92(8):1475–1485.

    Article  CAS  PubMed  Google Scholar 

  105. Brunton VG, MacPherson IR, Frame MC. Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochim Biophys Acta. 2004;1692(2–3):121–144.

    CAS  PubMed  Google Scholar 

  106. Alessandro R, Masiero L, Lapidos K, Spoonster J, Kohn EC. Endothelial cell spreading on type IV collagen and spreading-induced FAK phosphorylation is regulated by Ca2+ influx. Biochem Biophys Res Commun. 1998;248(3):635–640.

    Article  CAS  PubMed  Google Scholar 

  107. Salasznyk RM, Klees RF, Williams WA, Boskey A, Plopper GE. Focal adhesion kinase signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells. Exp Cell Res. 2007;313(1):22–37.

    Article  CAS  PubMed  Google Scholar 

  108. Mon NN, Ito S, Senga T, Hamaguchi M. FAK signaling in neoplastic disorders: a linkage between inflammation and cancer. Ann N Y Acad Sci. 2006;1086:199–212.

    Article  CAS  PubMed  Google Scholar 

  109. Yee KL, Weaver VM, Hammer DA. Integrin-mediated signalling through the MAP-kinase pathway. IET Syst Biol. 2008;2(1):8–15.

    Article  CAS  PubMed  Google Scholar 

  110. Halder J, Lin YG, Merritt WM, et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian cancer. Cancer Res. 2007;67:10976–10983.

    Article  CAS  PubMed  Google Scholar 

  111. Judson PL, He X, Cance WG, Van Le L. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer. 1999;86(8):1551–1556.

    Article  CAS  PubMed  Google Scholar 

  112. Sood AK, Coffin JE, Schneider GB, et al. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol. 2004;165(4):1087–1095.

    CAS  PubMed  Google Scholar 

  113. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, Parsons JT. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994;14(3):1680–1688.

    CAS  PubMed  Google Scholar 

  114. Ishizawar R, Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell. 2004;6(3):209–214.

    Article  CAS  PubMed  Google Scholar 

  115. Wiener JR, Windham TC, Estrella VC, et al. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol. 2003;88(1):73–79.

    Article  CAS  PubMed  Google Scholar 

  116. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007;29(11):2289–2308.

    Article  CAS  PubMed  Google Scholar 

  117. Chen HC, Appeddu PA, Isoda H, Guan JL. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J Biol Chem. 1996;271(42):26329–26334.

    Article  CAS  PubMed  Google Scholar 

  118. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99–102.

    Article  CAS  PubMed  Google Scholar 

  119. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene. 2000;19(19):2324–2330.

    Article  CAS  PubMed  Google Scholar 

  120. Mills GB, Kohn E, Lu Y, et al. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol. 2003;30(5 Suppl 16):93–104.

    Article  CAS  PubMed  Google Scholar 

  121. Hanks SK, Ryzhova L, Shin NY, Brabek J. Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci. 2003;8:d982–d996.

    Article  CAS  PubMed  Google Scholar 

  122. Davidson B, Goldberg I, Reich R, et al. AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol. 2003;90(2):248–257.

    Article  CAS  PubMed  Google Scholar 

  123. Casey RC, Burleson KM, Skubitz KM, et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol. 2001;159(6):2071–2080.

    CAS  PubMed  Google Scholar 

  124. Strobel T, Cannistra SA. Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol. 1999;73(3):362–367.

    Article  CAS  PubMed  Google Scholar 

  125. Khatib AM, Nip J, Fallavollita L, Lehmann M, Jensen G, Brodt P. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3. Int J Cancer. 2001;91(3):300–308.

    Article  CAS  PubMed  Google Scholar 

  126. Shibata K, Kikkawa F, Nawa A, Suganuma N, Hamaguchi M. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res. 1997;57(23):5416–5420.

    CAS  PubMed  Google Scholar 

  127. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 1996;85(5):683–693.

    Article  CAS  PubMed  Google Scholar 

  128. Said N, Najwer I, Motamed K. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol. 2007;170(3):1054–1063.

    Article  CAS  PubMed  Google Scholar 

  129. Yamamoto S, Tsuda H, Honda K, et al. Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol. 2007;20(12):1278–1285.

    Article  CAS  PubMed  Google Scholar 

  130. Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(6):901–918.

    Article  CAS  PubMed  Google Scholar 

  131. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.

    Article  CAS  PubMed  Google Scholar 

  132. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 1974;34(5):997–1004.

    CAS  PubMed  Google Scholar 

  133. Sieczkiewicz GJ, Hussain M, Kohn EC. Angiogenesis and metastasis. Cancer Treat Res. 2002;107:353–381.

    CAS  PubMed  Google Scholar 

  134. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol. 2002;55(6):348–359.

    Article  CAS  PubMed  Google Scholar 

  135. Barton DP, Cai A, Wendt K, Young M, Gamero A, De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res. 1997;3(9):1579–1586.

    CAS  PubMed  Google Scholar 

  136. Kohn EC. Angiogenesis in ovarian carcinoma: a formidable biomarker. Cancer. 1997;80(12):2219–2221.

    Article  CAS  PubMed  Google Scholar 

  137. Rasila KK, Burger RA, Smith H, Lee FC, Verschraegen C. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer. 2005;15(5):710–726.

    Article  CAS  PubMed  Google Scholar 

  138. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147(1):33–41.

    CAS  PubMed  Google Scholar 

  139. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165–5171.

    Article  CAS  PubMed  Google Scholar 

  140. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and anti-tumor activity. J Clin Oncol. 2008 Aug 1;26(22):3709–14.

    Google Scholar 

  141. Castilla MA, Neria F, Renedo G, et al. Tumor-induced endothelial cell activation: role of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2004;286(5):C1170–C1176.

    Article  CAS  PubMed  Google Scholar 

  142. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–1039.

    CAS  PubMed  Google Scholar 

  143. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103(2):159–165.

    Article  CAS  PubMed  Google Scholar 

  144. Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer. 2002;97(2):163–167.

    Article  CAS  PubMed  Google Scholar 

  145. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87(7):506–516.

    Article  CAS  PubMed  Google Scholar 

  146. Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 1996;56(7):1615–1620.

    CAS  PubMed  Google Scholar 

  147. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res. 2002;105(1):43–47.

    Article  CAS  PubMed  Google Scholar 

  148. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–4599.

    CAS  PubMed  Google Scholar 

  149. Azad NS, Annunziata C, Barrett T, et al. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results. J Clin Oncol (Meeting Abstracts). 2007;25(18 Suppl):3542.

    Google Scholar 

  150. Azad NS, Annunziata CM, Steinberg SM, et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer. 2008;112(8):1726–1732.

    Article  CAS  PubMed  Google Scholar 

  151. Belotti D, Rieppi M, Nicoletti MI, et al. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. Clin Cancer Res. 1996;2(10):1725–1730.

    CAS  PubMed  Google Scholar 

  152. Lu C, Kamat AA, Lin YG, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res. 2007;13(14):4209–4217.

    Article  CAS  PubMed  Google Scholar 

  153. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55–60.

    Article  CAS  PubMed  Google Scholar 

  154. Tsigkos S, Koutsilieris M, Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs. 2003;12(6):933–941.

    Article  CAS  PubMed  Google Scholar 

  155. Zhang L, Yang N, Park JW, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003;63(12):3403–3412.

    CAS  PubMed  Google Scholar 

  156. Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K. Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology. 2002;62(4):340–348.

    Article  CAS  PubMed  Google Scholar 

  157. Ornitz DM, Itoh N. Fibrolast growth factors. Genome Biol. 2001;2(3):REVIEWS3005.

    Google Scholar 

  158. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235(4787):442–447.

    Article  CAS  PubMed  Google Scholar 

  159. Crickard K, Gross JL, Crickard U, et al. Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol. 1994;55(2):277–284.

    Article  CAS  PubMed  Google Scholar 

  160. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994;86(5):356–361.

    Article  CAS  PubMed  Google Scholar 

  161. Birrer MJ, Johnson ME, Hao K, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007;25(16):2281–2287.

    Article  CAS  PubMed  Google Scholar 

  162. Batley BL, Doherty AM, Hamby JM, et al. Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 1998;62(2):143–150.

    Article  CAS  PubMed  Google Scholar 

  163. Kammasud N, Boonyarat C, Tsunoda S, et al. Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorg Med Chem Lett. 2007;17(17):4812–4818.

    Article  CAS  PubMed  Google Scholar 

  164. Landgren E, Klint P, Yokote K, Claesson-Welsh L. Fibroblast growth factor receptor-1 mediates chemotaxis independently of direct SH2-domain protein binding. Oncogene. 1998;17(3):283–291.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 20892, Bethesda, MD, USA

    Wafic M. ElMasri, Giovanna Casagrande, Ebony Hoskins, Daniel Kimm & Elise C. Kohn

Authors
  1. Wafic M. ElMasri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanna Casagrande
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ebony Hoskins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Kimm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elise C. Kohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elise C. Kohn .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Missouri, Hospital Dr. 1, Columbia, 65212, U.S.A.

    M. Sharon Stack

  2. School of Medicine, New York University, First Ave. 550, New York, 10016, U.S.A.

    David A. Fishman

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

ElMasri, W.M., Casagrande, G., Hoskins, E., Kimm, D., Kohn, E.C. (2009). Cell Adhesion in Ovarian Cancer. In: Stack, M., Fishman, D. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 149. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-98094-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-98094-2_14

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-98093-5

  • Online ISBN: 978-0-387-98094-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation